Vývoj a využití jiných PET radiofarmak než FDG na Masarykově onkologickém ústavu

Existence cyklotronu a PET centra ÚJV Řež, a.s., v Masarykově onkologickém ústavu umožňuje výzkumníkům z RECAMO a Masarykova onkologického ústavu zapojit se do výzkumu, vývoje a využití nových radiofarmak včetně látek označených krátce žijícími pozitronovými zářiči (zejména [¹¹C]). V současnosti zde vstupuje do I. fáze klinického hodnocení [¹¹C]-značený tracer L-[methyl-¹¹C]methionin a na oddělení nukleární medicíny jsou prováděny skeny s jinými PET radiofarmaky než fluordeoxyglukózou. Spolupráce by měla pokračovat i nadále a v budoucnu vyústit ve zpřístupnění více možností pro PET zobrazování v České republice.

Klíčová slova:
pozitronová emisní tomografie – radiofarmaka –3‘-deoxy-3‘-[¹⁸F]fluorothymidin – [¹⁸F]fluorocholin – [¹⁸F]fluorid sodný – L-[methyl-¹¹C]methionin

Autoři: J. Adam ^1,3; K. Bolcak ²; J. Kaderavek ³; F. Kuzel ³
Působiště autorů: Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic ¹; Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic ²; Division of Radiopharmaceuticals, UJV Rez, a. s., Husinec-Rez, Czech Republic ³
Vyšlo v časopise: Klin Onkol 2012; 25(Supplementum 2): 82-86

Práce byla podpořena Evropským fondem pro regionální rozvoj a státním rozpočtem České republiky (OP VaVpI – RECAMO, CZ.1.05/2.1.00/03.0101).

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.

Obdrženo: 10. 10. 2012
Přijato: 31. 10. 2012

Souhrn

Klíčová slova:
pozitronová emisní tomografie – radiofarmaka –3‘-deoxy-3‘-[¹⁸F]fluorothymidin – [¹⁸F]fluorocholin – [¹⁸F]fluorid sodný – L-[methyl-¹¹C]methionin

Zdroje

1. Som P, Atkins HL, Bandoypadhyay D et al. A Fluorinated Glucose Analog, 2-Fluoro-2-Deoxy-D-Glucose (F-18) – Nontoxic Tracer for Rapid Tumor-Detection. J Nucl Med 1980; 21(7): 670–675.

2. Roelcke U, Radü EW, von Ammon K et al. Alteration of Blood-Brain-Barrier in Human Brain-Tumors – Comparison of [F-18]Fluorodeoxyglucose, [C-11] Methionine and Rb-82 Using Pet. J Neurol Sci 1995; 132(1): 20–27.

3. Nakada K. The role of methionine PET in oncology. In: PET and Molecular Imaging: State of the Art and Future Perspectives, International Congress Series 1264. United Kingdom: Elsevier 2004: 88–94.

4. Hatakeyama T, Kawai I, Nishiyama Y et al. C-11-methionine (MET) and F-18-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 2008; 35(11): 2009–2017.

5. Been LB, Suurmeijer AJ, Cobben DC et al. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004; 31(12): 1659–1672.

6. Shields, AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 1998; 4(11): 1334–1336.

7. Rasey JS, Grierson JR, Wiens, LW et al. Uptake of labeled FLT correlates with thymidine kinase (TK1) activity in human tumor cells. J Nucl Med 2000; 41: 36–37.

8. Shields AF, Dohmen BM, Mangner TJ et al. Metabolism of F-18-FLT in patients. J Nucl Med 2000; 41: 36.

9. Buck AK, Halter G, Schirrmeister H et al. Imaging proliferation in lung tumors with PET: F-18-FLT versus F-18-FDG. J Nucl Med 2003; 44: 1426–1431.

10. Vesselle H, Grierson J, Muzi M et al. In vivo validation of 3 ‚ deoxy-3 ‚-[F-18]fluorothymidine ([F-18]FLT) as a proliferation imaging tracer in humans: Correlation of [F-18]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors Clin Cancer Res 2002; 8(11): 3315–3323.

11. Shields AF, Lawhorn-Crews JM, Briston DA et al. Analysis and reproducibility of 3 ‚-deoxy-3 ‚-[F-18]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 2008; 14(14): 4463–4468.

12. Vesselle H, Grierson J, Muzi M et al. F-18-Fluorothymidine PET imaging of nonsmall cell lung cancer (NSCLC): Comparison to (67)Ki proliferation index. J Nucl Med 2001; 42: 29.

13. Yap CS, Vranjesevic D, Schiepers C et al. A comparison between [F-18]fluorodeoxyglucose (FDG) and [F-18] 3‘-deoxy-3‘-fluorothymidine (FLT) uptake in solitary pulmonary nodules and lung cancer. J Nucl Med 2003; 44 (Suppl): 123.

14. Buck AK, Pitterle K, Schirrmeister H et al. [18F]FLT positron emission tomography for imaging Non-Hodgkin’s lymphoma and assessment of proliferative activity. J Nucl Med 2003; 44: 188–189.

15. Seitz U, Neumaier B, Wagner M et al. In vitro and in vivo evaluation of F-18-FLT as PET tracer in a murine lymphoma model. J Nucl Med 2002; 43: 27.

16. Direcks WGE, Berndsen SC, Proost N et al. [F-18]FDG and [F-18]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 2008; 99(3): 481–487.

17. Lineker A, Kermer C, Sulzbacher I et al. Uptake of F-18-FLT and F-18-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin 2008; 47(2): 80–85.

18. Cobben DC, van der Laan BF, Hoekstra HJ et al. Detection of mammary, laryngeal and soft tissue tumors with FLT-PET. J Nucl Med 2002; 43 (Suppl): 278.

19. Francis DL, Visvikis D, Costa DC et al. Potential impact of [F-18]3 ‚-deoxy-3 ‚-fluorothymidine versus [F-18]fluoro-2-deoxy-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30(7): 988–994.

20. Bauman G, Belhocine T, Kovacs M et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012; 15(1): 45–55.

21. Soyka JD, Muster MA, Schmid DT et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012; 39(6): 936–943.

22. Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Sem Nucl Med 1972; 2(1): 31–37.

23. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962; 3: 332–334.

24. Schirrmeister H, Guhlmann A, Elsner K et al. Sensitivity in Detecting Osseous Lesions Depends on Anatomic Localization: Planar Bone Scintigraphy Versus 18F PET. J Nucl Med 1999; 40(40): 1623–1629.

25. Schirrmeister H, Guhlmann A, Kotzerke J et al. Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer with Fluoride Ion and Positron Emission Tomography. J Clin Oncol 1999; 17(8): 2381–2389.

26. Petrén-Mallmin M, Andréasson I, Ljunggren O et al. Skeletal Metastases From Breast Cancer: Uptake of 18F-Fluoride Measured with PET in Correlation with CT. Skeletal Radiol 1998; 27(2): 72–76.

27. Grant FD, Fahey FH, Packard AB et al. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008; 49(1): 68–78.

28. Hetzel M, Arslandemir C, König HH et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003; 18(12): 2206–2214.

29. Even-Sapir E, Metser U, Flusser G et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004; 45(2): 272–278.

30. Even-Sapir E, Metser U, Mishani E et al. The detection of bone metastase in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2006; 47: 287–297.